POZ Focus : Pharma to the Fore - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
POZ Focus

Back to home » HIV 101 » POZ Focus

Table of Contents

Big Top

Financial Planning

Disability Decisions

Paying Off to Move Ahead

Affordable Care

Pharma to the Fore



HIV, The Basics

Immune System


What You're Talking About
Losing Hope (blog) (20 comments)

You Can't Hurry Love (14 comments)

I Watched Charlie Sheen on The Dr. Oz Show So You Don't Have To (blog) (14 comments)

Charlie Sheen S&%ts On 30 Years of AIDS Activism (blog) (13 comments)

Remember Their Names: World AIDS Day 2015 (blog) (12 comments)

Prudential to Offer Individual Life Insurance to People With HIV (7 comments)
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Pharma to the Fore

by Tim Horn

If you’re uninsured or struggling with prescription co-pays, pharmaceutical company programs might be able to help.

Do you lack health insurance but make too much money to qualify for government assistance? Are your prescription co-payments so high that you can’t afford other basic necessities? Help may be available from pharmaceutical companies in the form of patient assistance programs (PAPs) and co-pay programs.

Drug manufacturers have long maintained PAPs to help those who can’t afford their drugs. To qualify, recipients must prove that they have exhausted other options such as government programs and cannot afford private health insurance. They must also meet certain financial criteria, which will largely depend on personal income.

Several companies have also introduced co-payment assistance programs, available to people who have private health insurance with steep prescription co-pays. For example, GlaxoSmithKline’s Patient Savings Card program offers up to $100 per month in co-pay assistance for each GSK-product prescription for people who meet its eligibility criteria, starting with the first dollar that a person pays. If a person normally pays $100 a month in co-pays for a regimen consisting of Lexiva ($25), Norvir ($25) and Epzicom ($50), the Lexiva and Epzicom will be fully covered, reducing out-of-pocket expenses from $100 to $25 a month.

While co-pay programs do help, advocates caution that they’re only one aspect of choosing treatment wisely. Since the programs are not all the same, with some being more generous than others, some people may lean toward one regimen simply because it’s more affordable. “I hate the idea of people choosing drugs because it’s what they can afford,” says Lynda Dee of AIDS Action Baltimore, “but it’s better than not picking up the drugs at the pharmacy at all.”

Click here to download a copy of the Pharma Financial Programs chart.

Search: uninsured, co-pay, PAP, GSK, Lexiva, Norvir, Epzicom

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[ Go to top ]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.